Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup

References

• Fielding A. The treatment of adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2008:381–389.
   PubMedGoogle Scholar
• Ottmann OG, Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). Hematology Am Soc Hematol Educ Program 2009:371–381.
   PubMedGoogle Scholar
• Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535–1548.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446:758–764.
   PubMed Web of Science ®Google Scholar
• Familiades J, Bousquet M, Lafage-Pochitaloff M, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia 2009;23:1989–1998.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360:470–480.
   PubMed Web of Science ®Google Scholar
• Ben Abdelali R, Asnafi V, Leguay T, et al. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood 2011;118:5099–5107.
   PubMed Web of Science ®Google Scholar
• Bedford K, Macintyre E, Lhéritier V, et al. Minimal residual disease at 3 months, combined to the presence of IKZF1 deletion in B-lineage or absence of NOTCH1 pathway mutation in T-lineage, recapitulates the disease risk assessment in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia - a GRAALL Study. Blood 2011;118 (Suppl. 1): Abstract 572.
   Google Scholar
• Gokbuget N, Kneba M, Raff T, et al. Adults with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120:1868–1876.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:163–205.
   PubMed Web of Science ®Google Scholar
• Advani A, Jin T, Bolwell B, et al. A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapse. Leuk Lymphoma 2009;50:1126–1131.
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589–596.
   PubMed Web of Science ®Google Scholar
• Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907–1914.
   PubMed Web of Science ®Google Scholar
• Terwey TH, Massenkeil G, Tamm I, et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant 2008;42:791–798.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008;113:3186–3191.
   PubMed Web of Science ®Google Scholar
• Larson RA. Acute lymphoblastic leukemia: older patients and newer drugs. Hematology Am Soc Hematol Educ Program 2005: 131–136.
   Google Scholar
• Cohen MH, Johnson JR, Justice R, et al. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist 2008;13:709–714.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am 2009;23: 1121–1135, vii–viii.
   PubMed Web of Science ®Google Scholar
• Jeha S. Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine. Hematol Oncol Clin North Am 2009;23: 1137–1144, viii.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003;9:6335–6342.
   PubMed Web of Science ®Google Scholar
• Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2’-arabino-fluoro-2’-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999;5:2438–2444.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Popowycz F, Joseph B. Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. Curr Med Chem 2008;15:1072–1082.
   PubMed Web of Science ®Google Scholar
• Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 1996;56:3030–3037.
   PubMed Web of Science ®Google Scholar
• Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537–3543.
   PubMed Web of Science ®Google Scholar
• Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006;5:855–863.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Gil L, Derwich K, et al. Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study. Anticancer Res 2009;29:1643–1650.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Nowak BJ, Keating MJ, et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580–3589.
   PubMed Web of Science ®Google Scholar
• Karp JE, Ricklis RM, Balakrishnan K, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007;110:1762–1769.
   PubMed Web of Science ®Google Scholar
• Cooper T, Ayres M, Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005;55:361–368.
   PubMed Web of Science ®Google Scholar
• Faderl S, Gandhi V, O’Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940–947.
   PubMed Web of Science ®Google Scholar
• Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784–789.
   PubMed Web of Science ®Google Scholar
• Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917–1923.
   PubMed Web of Science ®Google Scholar
• Kearns P, Michel G, Nelken B, et al. A European phase II study (BIOV-111) of clofarabine (Evoltra®) in refractory and relapsed childhood acute lymphoblastic leukemia: final results. Blood 2007;110(Suppl. 1): Abstract 11.
   Google Scholar
• Hijiya N, Gaynon P, Barry E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009;23:2259–2264.
   PubMed Web of Science ®Google Scholar
• Hijiya N, Thomson B, Isakoff MS, et al. Phase II trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory/relapsed acute lymphoblastic leukemia. Blood 2011;118:6043–6049.
   PubMed Web of Science ®Google Scholar
• O’Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br J Haematol 2011;154:482–485.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 2009;147:371–378.
   PubMed Web of Science ®Google Scholar
• Miano M, Pistorio A, Putti MC, et al. Clofarabine, cyclophosphamide, and etoposide (CLOVE) treatment followed by SCT for relapsed or resistant acute leukaemia in paediatric patients. Presented at: 37th EBMT Annual Meeting, 3–6 April 2011, Paris, France.
   Google Scholar
• Cooper T, Alonzo TA, Gerbing RB, et al. AAML0523: a report from the Children’s Oncology Group on the safety of clofarabine in combination with cytarabine in pediatric patients with relapsed acute leukemia. Blood 2009;114 (Suppl.): Abstract 3076.
   Google Scholar
• Steinherz PG, Shukla N, Kobos R, et al. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer 2010;54:687–693.
   PubMed Web of Science ®Google Scholar
• Thomas X, Raffoux E, Elhamri M, et al. Clofarabine for the treatment of adult acute myeloid leukemia. Future Oncol 2009;5: 1197–1210.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167–1173.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638–1645.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379–2386.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010;28:2389–2395.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Garcia-Manero G, et al. Frontline therapy for older patients (pts) with acute myeloid leukemia (AML): clofarabine plus low-dose cytarabine induction followed by prolonged consolidation with clofarabine plus low-dose cytarabine alternating with decitabine. Blood 2010;116 (Suppl. 1): Abstract 336.
   Google Scholar
• Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549–555.
   PubMed Web of Science ®Google Scholar
• Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 2011;155:182–189.
   PubMed Web of Science ®Google Scholar
• Thomas X, Lobe I, Raffoux E, et al. Intensive consolidation with clofarabine and intermediate-dose cytarabine (CLARA) in patients with high-risk AML in first CR: the ALFA-0702 pilot study. Blood 2008;112(Suppl. 1): Abstract 1934.
   Google Scholar
• Faderl S, Ferrajoli A, Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008;113: 2090–2096.
   PubMed Web of Science ®Google Scholar
• Naqvi K, Ravandi F, Kantarjian H, et al. Phase II study of the combination of clofarabine plus idarubicin and cytarabine (CIA) in patients with relapsed/refractory acute myeloid leukemia (AML). Blood 2010;116(Suppl. 1): Abstract 1061.
   Google Scholar
• Faderl S, Thomas DA, Gandhi V, et al. Phase I/II study of clofarabine plus cyclophosphamide in adults with relapsed and refractory acute lymphoblastic leukemia (ALL). Blood 2007; 110(Suppl. 1): Abstract 4335.
   PubMed Web of Science ®Google Scholar
• Agura E, Cooper B, Holmes H, et al. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 2011;16:197–206.
   PubMed Web of Science ®Google Scholar
• McGregor BA, Brown AW, Osswald MB, et al. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol 2009;84:228–230.
   PubMed Web of Science ®Google Scholar
• Miano M, Pistorio A, Putti MC, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma 2012;53:1693–1698.
   PubMed Web of Science ®Google Scholar
• Dressel A, Kwari M, McGreal AM. Nursing considerations for optimal outpatient management of adult patients with leukemia treated with clofarabine. Clin J Oncol Nurs 2011;15:E13–E23.
   Google Scholar
• McDonald LR, McCarthy CH. Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children. Clin J Oncol Nurs 2006;10:809–815.
   PubMedGoogle Scholar
• Genzyme. Clolar®/Evoltra®. Summary of product characteristics.2011.
   Google Scholar
• Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108:45–51.
   PubMed Web of Science ®Google Scholar
• Choi J, Foss F. Efficacy of low dose clofarabine in refractory precursor T-acute lymphoblastic leukemia. Yale J Biol Med 2006;79: 169–172.
   PubMedGoogle Scholar
• Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest Oncology Group study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol 2010;151:430–434.
   PubMed Web of Science ®Google Scholar
• Papayannidis C, Derenzini E, Iacobucci I, et al. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. Am J Hematol 2009;84:849–850.
   PubMed Web of Science ®Google Scholar
• Chawla B, Kanate AS, Osman S, et al. Clofarabine in combination with cyclophosphamide for treatment of relapsed/refractory acute leukemia in adult patients. Blood 2010;116(Suppl. 1): Abstract 4367.
   Google Scholar
• Grigoleit GU, Kapp M, Tan SM, et al. Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series. Leuk Lymphoma 2009;50:2071–2074.
   PubMed Web of Science ®Google Scholar
• Vitale A, Grammatico S, Capria S, et al. Advanced Philadelphia chromosome positive acute lymphoblastic leukemia patients relapsed after treatment with tyrosine-kinase inhibitors: successful response to clofarabine and cyclophosphamide. Haematologica 2009;94: 1471–1473.
   PubMed Web of Science ®Google Scholar
• Domenech C, Mercier M, Plouvier E, et al. First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: results of the Cooprall-97 study. Eur J Cancer 2008;44:2461–2469.
   PubMed Web of Science ®Google Scholar
• Pigneux A, Sauvezie M, Vey N, et al. Clofarabine combinations in adults with refractory/relapsed acute lymphoblastic leukemia (ALL): a GRAALL report. Blood 2011;118(Suppl. 1): Abstract 2586.
   PubMed Web of Science ®Google Scholar
• Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother 2007;8:1977–1984.
   PubMed Web of Science ®Google Scholar
• Domenech C, Thomas X, Chabaud S, et al. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol 2011;153:58–65.
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Leguay T, Thomas X, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica 2011;96:245–252.
   PubMed Web of Science ®Google Scholar
• Heffner L Jr. A new formulation of vincristine for acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2011;9:314–316.
   PubMedGoogle Scholar
• Larson RA. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. Semin Oncol 2007;34: S13–S20.
   Google Scholar
• Chevallier P, Robillard N, Charbonnier A, et al. Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. Blood 2012;119:2474–2477.
   PubMed Web of Science ®Google Scholar
• Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 2008;26:3756–3762.
   PubMed Web of Science ®Google Scholar
• Topp M, Goekbuget N, Zugmaier G, et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing phase II trial. Blood 2011;118(Suppl. 1): Abstract 252.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Wilhelm K, Ravandi F, et al. Inotuzumab ozogamicin (IO) is an effective salvage therapy that allows for allogeneic hematopoietic stem cell transplantation (HSCT) in remission in patients with advanced acute lymphoblastic leukemia (ALL). Blood 2011;118(Suppl. 1): Abstract 3102.
   Google Scholar
• Lock RB, Carol H, Szymanska B, et al. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Mol Cancer Ther 2011;10(Suppl.): Abstract C107.
   Google Scholar
• Schult C, Dahlhaus M, Glass A, et al. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res 2012;32:463–474.
   PubMed Web of Science ®Google Scholar
• Groth C, Fortini ME. Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol 2012;23:465–472.
   PubMed Web of Science ®Google Scholar
• Messinger Y, Gaynon P, Sposto R, et al. Bortezomib combined with VXLD chemotherapy is highly effective in advanced B-lineage acute lymphoblastic leukemia allowing early study termination due to efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) consortium phase II study. Blood 2011;118(Suppl. 1): Abstract 251.
   Google Scholar
• Garcia-Manero G, Thomas D, Rytting M, et al. A phase 1 study of dose-dense 5-aza-20-deoxycitidine (decitabine) in relapsed refractory acute lymphocytic leukemia (ALL). Blood 2009; 114(Suppl. 1): Abstract 2030.
   PubMed Web of Science ®Google Scholar
• Mummery A, Narendran A, Lee KY. Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. Curr Cancer Drug Targets 2011;11:882–893.
   PubMed Web of Science ®Google Scholar
• Barba P, Sampol A, Calbacho M, et al. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience. Am J Hematol 2012;87:631–634.
   PubMed Web of Science ®Google Scholar